Research

researcher looking at a microscope

Zura Bio Joins NAAF’s 2023 Industry Partner Program

NAAF is pleased to announce that Zura Bio has joined the Industry Partner Program at the Bronze membership level. Zura…

Puzzle pieces with medical terms like clincal trial

Alopecia Areata Research Depends on Clinical Trial Volunteers

Media reports of two newly approved drugs for treating alopecia areata brought good news to many people living with the…

FDA Approves LITFULO™ (Ritlecitinib) for Adults and Children ages 12+ with Severe Alopecia Areata

Today, the U.S. Food and Drug Administration (FDA) approved LITFULO™ for severe alopecia areata, marking the second FDA-approved treatment for…

volunteer hands 2

New Research: Prevalence of Alopecia Areata across Races and Ethnicities

Does alopecia areata (AA) affect all races and ethnic groups equally? If yes, why is this important? Knowing AA prevalence…

New Clinical Trial Data Published for Ritlecitinib

Results from a clinical trial for a new treatment for alopecia areata were published in the medical journal The Lancet…

Treatment Development Program Impact Report

As we come to the close of 2022, we look upon these past 12 months as among the most pivotal…

Recent Survey Study Results

When you participate in a survey that comes to you in a NAAF email, what happens to your responses? For…

FDA Accepts Filing of New Drug Application (NDA)

Today we received the welcome news that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug…

FDA Approves Olumiant™ (baricitinib) for Adults with Severe Alopecia Areata

Today, history was made as the U.S. Food and Drug Administration (FDA) approved Olumiant™ for alopecia areata, marking the first…